IOL Chemicals spurts after completing de-bottlenecking project

Image
Capital Market
Last Updated : Nov 19 2015 | 12:28 PM IST

IOL Chemicals & Pharmaceuticals jumped 9.17% to Rs 92.85 at 11:24 IST on BSE after the company announced completion of de-bottlenecking project for its Ibuprofen manufacturing facilities at Barnala.

The company made announcement during market hours today, 19 November 2015.

Meanwhile, the S&P BSE Sensex was up 252.85 points, or 0.99%, to 25,735.37

On BSE, so far 67,000 shares were traded in the counter, compared with an average volume of 46,809 shares in the past one quarter.

The stock hit a high of Rs 96.40 and a low of Rs 85.25 so far during the day. The stock had hit a 52-week high of Rs 113.90 on 21 July 2015. The stock had hit a 52-week low of Rs 24.50 on 24 March 2015.

The stock had outperformed the market over the past one month till 18 November 2015, rising 4.68% compared with 6.36% fall in the Sensex. The scrip had also outperformed the market in past one quarter, gaining 12.5% as against Sensex's 8.44% decline.

The small-cap company has equity capital of Rs 54.58 crore. Face value per share is Rs 10.

IOL Chemicals and Pharmaceuticals (IOLCP) announced completion of de-bottlenecking/ re-engineering project for its Ibuprofen manufacturing facilities at Barnala with project cost of Rs 24 crore and commenced the enhanced production from today, 19 November 2015. Post this completion, the capacity of Ibuprofen plant increased to 6200 TPA. These approvals will facilitate the company to build and sustaining the growth by its API business in coming years, being the only integrated Ibuprofen player globally, by exploring the higher value regulated markets, IOLCP said.

IOL Chemicals & Pharmaceuticals reported net loss of Rs 12.93 crore in Q2 September 2015, higher than net loss of Rs 9.75 crore in Q2 September 2014. Total income rose 30.3% to Rs 158.47 crore in Q2 September 2015 over Q2 September 2014.

IOL Chemicals and Pharmaceuticals is one of the leading generic pharmaceuticals companies and is significant player in the speciality chemicals space.

Powered by Capital Market - Live News

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 19 2015 | 11:37 AM IST

Next Story